or Try an Advanced Search...

    Liver Disease Stocks List

    Symbol Grade Name % Change
    GALT A Galectin Therapeutics Inc. -0.30
    ALGS D Aligos Therapeutics, Inc. -5.43
    GYRE D Gyre Therapeutics, Inc. 0.65
    TARA D ArTara Therapeutics, Inc. -4.00
    GNFT D GENFIT S.A. -5.01
    BLTE F Belite Bio, Inc. -3.38
    BFRG F Bullfrog AI Holdings, Inc -10.60
    GILD F Gilead Sciences, Inc. 0.91
    HEPA F Hepion Pharmaceuticals, Inc. -4.82
    MIRM F Mirum Pharmaceuticals, Inc. 1.02
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
    Related Stock Lists: Hepatitis Medicine Non Alcoholic Fatty Liver Disease Steatohepatitis Biopharmaceutical Alcohol Hepatology Chronic Liver Disease Chronic Liver Diseases Clinical Medicine Coronavirus Drug Development Fatty Liver Disease Gilead Sciences Hepatitis B Hepatotoxins Lipid Liver Liver Fibrosis Primary Biliary Cholangitis

    Related ETFs - A few ETFs which own one or more of the above listed Liver Disease stocks.

    Symbol Grade Name Weight
    IBBQ D Invesco Nasdaq Biotechnology ETF 8.25
    IBB D iShares Nasdaq Biotechnology Index Fund 8.25
    BBH D Market Vectors Biotech ETF 7.99
    BIS A ProShares UltraShort Nasdaq Biotechnology 7.41
    BIB D ProShares Ultra Nasdaq Biotechnology 6.1
    View all Liver Disease ETFs...
    Compare ETFs
    Compare IBB to BIB Compare IBBQ to BBH Compare IBBQ to BIB

        Liver Disease Stocks Recent News

        Date Stock Title
        Apr 19 HEPA Hepion ends Phase 2 study for NASH drug due to cash restraints
        Apr 19 HEPA Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
        Apr 19 GILD FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
        Apr 18 GILD US FDA mandates label updates on CAR-T cancer therapies
        Apr 18 GILD Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
        Apr 18 GILD Gilead Sciences Publishes 2023 ESG Impact Report
        Apr 18 MIRM Stifel starts Mirum at buy, cites IBATi drug potential
        Apr 18 GILD Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
        Apr 17 GILD GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
        Apr 16 GILD Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
        Apr 16 GILD Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
        Apr 15 GILD Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
        Apr 15 GILD GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
        Apr 15 GILD GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG
        Apr 13 GYRE Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
        Related Stock Lists: Hepatitis Medicine Non Alcoholic Fatty Liver Disease Steatohepatitis Biopharmaceutical Alcohol Hepatology Chronic Liver Disease Chronic Liver Diseases Clinical Medicine Coronavirus Drug Development Fatty Liver Disease Gilead Sciences Hepatitis B Hepatotoxins Lipid Liver Liver Fibrosis Primary Biliary Cholangitis
        Liver Disease

        Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the course of the problem lasts long, chronic liver disease ensues.

        More about Liver Disease
        Browse All Tags